No Cover Image

Journal article 260 views 64 downloads

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Adie Viljoen, Steve Bain Orcid Logo

Endocrinology and Metabolism, Volume: 38, Issue: 1, Pages: 25 - 33

Swansea University Author: Steve Bain Orcid Logo

  • 62654_VoR.pdf

    PDF | Version of Record

    Copyright © 2023 Korean Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License

    Download (314.93KB)

Check full text

DOI (Published version): 10.3803/enm.2022.1642

Abstract

The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations b...

Full description

Published in: Endocrinology and Metabolism
ISSN: 2093-596X 2093-5978
Published: Korean Endocrine Society 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa62654
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-02-14T08:50:15Z
last_indexed 2023-03-07T04:17:50Z
id cronfa62654
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-03-06T10:51:24.2323767</datestamp><bib-version>v2</bib-version><id>62654</id><entry>2023-02-14</entry><title>Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-02-14</date><deptcode>BMS</deptcode><abstract>The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer&#x2019;s disease.</abstract><type>Journal Article</type><journal>Endocrinology and Metabolism</journal><volume>38</volume><journalNumber>1</journalNumber><paginationStart>25</paginationStart><paginationEnd>33</paginationEnd><publisher>Korean Endocrine Society</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2093-596X</issnPrint><issnElectronic>2093-5978</issnElectronic><keywords>Glucagon-like peptide 1; Diabetes mellitus, type 2; Renal insufficiency, chronic</keywords><publishedDay>6</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-02-06</publishedDate><doi>10.3803/enm.2022.1642</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2023-03-06T10:51:24.2323767</lastEdited><Created>2023-02-14T08:49:02.2160982</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Adie</firstname><surname>Viljoen</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author></authors><documents><document><filename>62654__26745__7f2181f2bc4c46d98a476215319909c9.pdf</filename><originalFilename>62654_VoR.pdf</originalFilename><uploaded>2023-03-06T10:49:27.6749583</uploaded><type>Output</type><contentLength>322484</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright &#xA9; 2023 Korean Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2023-03-06T10:51:24.2323767 v2 62654 2023-02-14 Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2023-02-14 BMS The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease. Journal Article Endocrinology and Metabolism 38 1 25 33 Korean Endocrine Society 2093-596X 2093-5978 Glucagon-like peptide 1; Diabetes mellitus, type 2; Renal insufficiency, chronic 6 2 2023 2023-02-06 10.3803/enm.2022.1642 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2023-03-06T10:51:24.2323767 2023-02-14T08:49:02.2160982 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Adie Viljoen 1 Steve Bain 0000-0001-8519-4964 2 62654__26745__7f2181f2bc4c46d98a476215319909c9.pdf 62654_VoR.pdf 2023-03-06T10:49:27.6749583 Output 322484 application/pdf Version of Record true Copyright © 2023 Korean Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License true eng https://creativecommons.org/licenses/by-nc/4.0/
title Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
spellingShingle Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Steve Bain
title_short Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
title_full Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
title_fullStr Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
title_full_unstemmed Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
title_sort Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Adie Viljoen
Steve Bain
format Journal article
container_title Endocrinology and Metabolism
container_volume 38
container_issue 1
container_start_page 25
publishDate 2023
institution Swansea University
issn 2093-596X
2093-5978
doi_str_mv 10.3803/enm.2022.1642
publisher Korean Endocrine Society
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.
published_date 2023-02-06T04:22:26Z
_version_ 1763754478753808384
score 11.012678

Similar Items